Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Revenue (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Revenue for 5 consecutive years, with -$63462.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 155.33% year-over-year to -$63462.0, compared with a TTM value of -$240664.0 through Dec 2025, down 118.2%, and an annual FY2024 reading of $1.3 million, down 40.94% over the prior year.
  • Revenue was -$63462.0 for Q4 2025 at SAB Biotherapeutics, down from -$43292.0 in the prior quarter.
  • Across five years, Revenue topped out at $18.2 million in Q2 2021 and bottomed at -$69565.0 in Q1 2025.
  • Average Revenue over 5 years is $4.6 million, with a median of $944575.0 recorded in 2024.
  • The sharpest move saw Revenue soared 207.7% in 2024, then crashed 155.33% in 2025.
  • Year by year, Revenue stood at $11.1 million in 2021, then crashed by 80.46% to $2.2 million in 2022, then crashed by 85.88% to $305011.0 in 2023, then crashed by 62.4% to $114698.0 in 2024, then plummeted by 155.33% to -$63462.0 in 2025.
  • Business Quant data shows Revenue for SABS at -$63462.0 in Q4 2025, -$43292.0 in Q3 2025, and -$64345.0 in Q2 2025.